Apex Labs Receives Approval for US-Based Secondary GMP Psilocybin Supplier by Health CanadaUSA – EnglishUSA – English

VANCOUVER, BC, June 9, 2023 /CNW/ – Apex Labs Ltd. (APEX or the Company), a pharmaceutical company transforming the standard of mental health care with clinically proven psilocybin treatments, announces Health Canada Approval of the company’s secondary US-based supplier of Good Manufacturing Practices (GMP) psilocybin Active Pharmaceutical Ingredient (API) in addition to its existing primary…

Source